63 results about "Peripheral Blood Stem Cells" patented technology

The present invention relates to methods, kits and compositions for expansion of hematopoietic stem / progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem / progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem / progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem / progenitor cells, placental cord blood stem / progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem / progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and / or long-term in vivo repopulation benefits.

The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or "pre-disease" state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) treating a patient suffering from organ disease with PBSC. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the organ disease is monitored by using an ultrasound unit.

The present invention is a tissue engineering skin containing the peripheral blood stem cell and the preparation method. The present invention puts the peripheral blood stem cell and the skin fibroblast cell inside the biological frame. The active tissue engineering skin containing the peripheral blood stem cell is built by planting the epidermal cell on the surface. The tissue engineering skin is similar to the natural skin tissue in structure. Compared with the present skin replacing product, the present invention has properties of improving the blood supply in the wound and promoting the wound healing. The present invention can improve the elastic and toughness properties of the skin as well as the mechanical wear tolerance. The present invention can also reduce the scar proliferation and improve the healing quality. The present invention can improve the success rate of the artificial skin planting and can be effectively applied in repairing the skin defect, which is hard to heal.

The present invention is related generally to embryonic-like stem cells isolated from adult human peripheral blood, designated herein as peripheral blood-stem cells (PB-SC), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to other types of cells. These cells are, therefore, suitable for use in stem cell-based therapies, particularly autologous stem cell therapies, for the treatment of various diseases such as neurodegenerative diseases, autoimmune diseases, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects.

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

The present invention is directed to the process of preparing an expanded peripheral blood stem cell composition, preparing a TVEMF-expanded peripheral blood stem cell composition, methods of producing the same, and to repair of tissue and / or function with expanded, and TVEMF-expanded, peripheral blood stem cells.

A herbal medicinal composition and a herbal medicinal extract for inducing production of peripheral blood stem cells and a method for preparing the same. The herbal medicinal composition contains herbal medicinal herbs disclosed herein such as Cinnamomum Ramulus, Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma, Jujubae Fructus, Anelicae Radix, and Astragali Radix.

The present invention relates to the field of hematopoietic stem cells. More specifically, the present invention provides methods and composition useful for peripheral blood stem cell mobilization. In one embodiment, a method of treating an organ transplant recipient comprises administering to the recipient a low dose of Tacrolimus in an amount sufficient to mobilize stem cells to the peripheral blood of the recipient. In a specific embodiment, the low dose of Tacrolimus is in the range of about 0.05 mg / kg to about 0.5 mg / kg.

An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.

This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells.

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA and VEGF165; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) injecting the PBSC into a patient suffering from chronic heart disease. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the chronic heart disease is monitored by using an echocardiogram unit.

The invention relates to the technical field of medical instruments and discloses a peripheral blood stem cell and marrow blood reinfusion device. The peripheral blood stem cell and marrow blood reinfusion device comprises an infusion tube; the infusion tube is made of a non-toxic and harmless material; the outer side of the infusion tube is fixedly provided with a pressure control bag and a protective shell; the pressure control bag is arranged above the protective shell; a partition plate is fixedly connected to the interior of the pressure control bag; and a communication hole is formed inthe left side of the top of the partition plate. For the peripheral blood stem cell and marrow blood reinfusion device, by installing the pressure control bag on the infusion tube, when in use, as blood below the partition plate in the pressure control bag slowly flows out, a floating plate slowly descends; when a pulling rope is straightened, a floating block starts to drive a pull rod to move downwards through the pulling rope, the pull rod pulls a sliding rod, the sliding rod vertically moves downwards, and a clamping rod is driven to move rightwards to enter a moving cavity through an inclined through hole; and the upper side and the lower side of the partition plate are communicated through an L-shaped hole, blood above the partition plate flows to the lower side, and after the clamping rod moves to the position below the partition plate, the structure is reset.

A herbal medicinal composition and a herbal medicinal extract for inducing production of peripheral blood stem cells and a method for preparing the same. The herbal medicinal composition contains herbal medicinal herbs disclosed herein such as Cinnamomum Ramulus, Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma, Jujubae Fructus, Anelicae Radix, and Astragali Radix.